Evaluation of anticancer potential of glutamine metabolism modulation in multiple myeloma sensitive and resistant to chemotherapy.
2016/21/N/NZ5/02585
Keywords
Descriptors
- NZ5_7: Leczenie chorób człowieka
- NZ5_3: Patogeneza chorób człowieka
- NZ3_1: Biologia komórki
Panel
NZ5 – Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution
Uniwersytet Warszawski, Centrum Nowych Technologii Uniwersytetu Warszawskiego
Voivodeship: mazowieckie
Principal investigator (from the host institution)
Number of co-investigators in the project: 2
Call
PRELUDIUM 11 – announced on 2016-03-15
- Amount awarded
- 99 960 PLN
- Project start date
- 2017-02-03
- Project end date
- 2020-02-02
- Project duration
- 36 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors
- Authors:
- Monika K.Prelowska, Dawid Mehlich, M. Talha Ugurlu, Hanna Kedzierska, Aleksandra Cwiek, Artur Kosnik, Klaudia Kaminska, Anna A. Marusiak, Dominika Nowis
- Academic press:
- Cancer Letters (year: 2021, volume: 507, pages: 13-25), Publisher: Elsevier
- Status:
- Published
- DOI:
- 10.1016/j.canlet.2021.02.020 – link to the publication